❌

Normal view

Received β€” 23 February 2026 ⏭ Favourites
  • βœ‡Latest Science News -- ScienceDaily
  • Generative AI analyzes medical data faster than human research teams
    Researchers tested whether generative AI could handle complex medical datasets as well as human experts. In some cases, the AI matched or outperformed teams that had spent months building prediction models. By generating usable analytical code from precise prompts, the systems dramatically reduced the time needed to process health data. The findings hint at a future where AI helps scientists move faster from data to discovery.
     
  • 🏷️
  • ↗️

Generative AI analyzes medical data faster than human research teams

βœ‡Latest Science News -- ScienceDaily
21 February 2026 at 19:17
Researchers tested whether generative AI could handle complex medical datasets as well as human experts. In some cases, the AI matched or outperformed teams that had spent months building prediction models. By generating usable analytical code from precise prompts, the systems dramatically reduced the time needed to process health data. The findings hint at a future where AI helps scientists move faster from data to discovery.

Evolving roles of liquid biopsy in precision medicine for colorectal cancer: from single-gene analysis to broad genomic profiling

βœ‡MRD
By: Giulia Martini Β· Stefania Napolitano Β· Davide Ciardiello Β· Luca Boscolo Bielo Β· Erika Martinelli Β· Teresa Troiani Β· Maria Giulia Zampino Β· Nicola Fazio Β· Giuseppe Curigliano Β· Fortunato Ciardiello
20 February 2026 at 19:00

Nat Rev Clin Oncol. 2026 Feb 20. doi: 10.1038/s41571-026-01126-1. Online ahead of print.

ABSTRACT

Colorectal cancer (CRC) is a heterogeneous malignancy, with various alterations in molecular signalling pathways driving disease progression and resistance to therapy. Liquid biopsy, as a source of circulating tumour DNA (ctDNA), has been utilized to characterize tumour molecular heterogeneity, facilitating the identification of actionable targets for precision medicine-guided therapies and the detection of emerging genomic drivers of drug resistance in patients with metastatic CRC. In addition, liquid biopsy-based analysis of ctDNA has been validated as a tool for detecting minimal residual disease (MRD) following locoregional treatment in patients with localized colon or rectal cancer, offering improved prognostic stratification and supporting the tailoring of adjuvant systemic therapy. Methodological evolution from PCR analysis of a few known mutations in one gene or a small panel of genes to the assessment of hundreds of genes and pathogenic variants by next-generation sequencing has enabled comprehensive genomic profiling (CGP), thereby improving knowledge of cancer molecular complexity at the individual patient level. In this respect, liquid biopsy-based CGP is an easily repeatable and minimally invasive approach that can provide a dynamic portrait of CRC molecular heterogeneity to guide personalized and adaptive treatment based on biomarkers of response and resistance. In this Review, we discuss current and potential roles of liquid biopsy-based ctDNA analysis in the clinical management of metastatic CRC. We also discuss the evidence supporting implementation of liquid biopsy-based assessment of MRD to refine the management of locoregional CRC and potentially improve cure rates while reducing overtreatment of many patients.

PMID:41720942 | DOI:10.1038/s41571-026-01126-1

There are no more articles
❌